Note: As per the original trial protocol, as part of the risk-adapted approach, about 20% of patients allocated TARGIT-IORT were expected to receive whole breast radiotherapy due to factors found in post-operative microscopic examination of the tumour specimen.
This approach allows individualised and personalised treatment for each patient.
A tool to help decide when to use of additional radiotherapy is available at here or https://targit.org.uk/addrt
The short-term and long-term results of those received additional whole breast radiotherapy did not differ from those who did not or from those who were allocated whole breast radiotherapy.
At 5 years' complete follow up, local recurrence (LR) and death rates (Deaths) were:
Allocated TARGIT-IORT during lumpectomy LR 2.11%, Deaths 3.7%,
Allocated TARGIT-IORT received no EBRT LR 2.35%, Deaths 3.1%
Allocated Whole breast radiotherapy LR 0.95%, Deaths 4.8%
The local control rates are shown in the figure below:
References
1. Vaidya, J.S., et al., Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 2020. 370: p. m2836. https://www.bmj.com/content/370/bmj.m2836.pdf
2. Vaidya, J.S., et al., New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer. Br J Cancer, 2021. 125(3): p. 380-389. https://www.nature.com/articles/s41416-021-01440-8.pdf
3. Vaidya, J.S., et al., Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment. British Journal of Cancer, 2021. https://www.nature.com/articles/s41416-020-01233-5.pdf
5. Vaidya, J.S., et al., The TARGIT-A Randomized Trial: TARGIT-IORT Versus Whole Breast Radiation Therapy: Long-Term Local Control and Survival. Int J Radiat Oncol Biol Phys, 2023. 115(1): p. 77 82. https://www.redjournal.org/article/S0360-3016(22)03132-7/fulltext
4. Vaidya, J.S., et al., Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) to improve breast cancer treatment – better for patients, better for health care systems. Frontiers in Oncology, 2022. 12: p. 786515. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.786515/full